| Title: | Continuous glucose monitoring-based time-in-range usinginsulin glargine 300 units/ml versus insulin degludec100 units/ml in type 1 diabetes : the head-to-head randomizedcontrolled InRange trial |
|---|
| Authors: | ID Battelino, Tadej (Author)
ID Danne, Thomas (Author)
ID Edelman, Steve (Author)
ID Choudhary, Pratik (Author)
ID Renard, Eric (Author)
ID Westerbacka, Jukka (Author)
ID Mukherjee, Bhaswati (Author)
ID Pilorget, Valerie (Author)
ID Coudert, Mathieu (Author)
ID Bergenstal, Richard (Author) |
|---|
| Files: |  https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14898
https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14898
|
|---|
| Language: | English |
|---|
| Work type: | Unknown |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: | UM - University of Maribor
|
|---|
| Abstract: | Aim:To use continuous glucose monitoring (CGM)-based time-in-range (TIR) as a pri-mary efficacy endpoint to compare the second-generation basal insulin(BI) analogues insulin glargine 300 U/ml (Gla-300) and insulin degludec 100 U/ml(IDeg-100) in adults with type 1 diabetes (T1D).Materials and Methods:InRange was a 12-week, multicentre, randomized, active-controlled, parallel-group, open-label study comparing glucose TIR and variabilitybetween Gla-300 and IDeg-100 using blinded 20-day CGM profiles. The inclusioncriteria consisted of adults with T1D treated with multiple daily injections, using BIonce daily and rapid-acting insulin analogues for at least 1 year, with an HbA1c of7% or higher and of 10% or less at screening.Results:Overall, 343 participants were randomized: 172 received Gla-300 and 171 IDeg-100. Non-inferiority (10% relative margin)of Gla-300 versus IDeg-100 was shown for theprimary endpoint (percentage TIR≥70 to≤180 mg/dl): least squares (LS) mean (95% con-fidence interval) 52.74% (51.06%, 54.42%) for Gla-300 and 55.09% (53.34%, 56.84%) forIDeg-100; LS mean difference (non-inferiority): 3.16% (0.88%, 5.44%) (non-inferiorityP=.0067). Non-inferiority was shown on glucose total coefficient of variation (main second-ary endpoint): LS mean 39.91% (39.20%, 40.61%) and 41.22% (40.49%, 41.95%), respec-tively; LS mean difference (non-inferiority)5.44% (6.50%,4.38%) (non-inferiorityP< .0001). Superiority of Gla-300 over IDeg-100 was not shown on TIR. Occurrences ofself-measured and CGM-derived hypoglycaemia were comparable between treatmentgroups. Safety profiles were consistent with known profiles, with no unexpected findings.Conclusions:Using clinically relevant CGM metrics, InRange shows that Gla-300 isnon-inferior to IDeg-100 in people with T1D, with comparable hypoglycaemia andsafety profiles. |
|---|
| Keywords: | basal insulin, continuous glucose monitoring, glycaemic control, insulin analogues, randomized trial, type 1 diabetes |
|---|
| Submitted for review: | 01.01.2023 |
|---|
| Article acceptance date: | 02.02.2023 |
|---|
| Publication date: | 01.01.2023 |
|---|
| Publisher: | a |
|---|
| Year of publishing: | 2023 |
|---|
| Number of pages: | 545-555 str. |
|---|
| Numbering: | Vol. 25, iss. 2, [article no.] 14898 |
|---|
| Source: | a |
|---|
| COBISS.SI-ID: | 143145987  |
|---|
| UDC: | 616.379 |
|---|
| ISSN on article: | 1463-1326 |
|---|
| DOI: | 10.1111/dom.14898 |
|---|
| Data col. methods: | Interview:E-mail
Interview:Web based |
|---|
| Note: | a |
|---|
| Publication date in OS2: | 11.08.2025 |
|---|
| Views: | 12 |
|---|
| Downloads: | 0 |
|---|
| Metadata: |    |
|---|
| Categories: | Document is not linked to any category. |
|---|
|
:
|
Copy citation |
|---|
| | | | Average score: | (0 votes) |
|---|
| Your score: | Voting is allowed only for logged in users. |
|---|
| Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
